Back to discover
Drug

Ropivacaine

In clinical development
Emerging researchLate-stage development
Also known as (S)-(-)-1-propyl-2',6'-pipecoloxylidide, (S)-ropivacaine, Naropin, Ropivacaina+4 more

(S)-(-)-1-propyl-2',6'-pipecoloxylidide, (S)-ropivacaine, Naropin, Ropivacaina, ropivicaine, L-N-n-propylpipecolic acid-2,6-xylidide, Ropivacaine Hydrochloride, Ropivacainum.

2
Research papers
25
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ropivacaine
Aliases & brands
(S)-(-)-1-propyl-2',6'-pipecoloxylidide(S)-ropivacaineNaropinRopivacainaropivicaineL-N-n-propylpipecolic acid-2,6-xylidideRopivacaine HydrochlorideRopivacainum
RxNorm CUI
35780
ChEMBL ID
CHEMBL1077896
UNII
7IO5LYA57N

Clinical trials

192 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
192
registered trials across all phases
LATEST COMPLETION 2026
25
Active studies
21
Recruiting
167
Late-stage (III+)
103
Completed
64
Discontinued
PHASE DISTRIBUTIONn = 192
Early Phase 16Phase 15Phase 1 / 23Phase 211Phase 2 / 36Phase 321Phase 480Phase N / A60

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20202024
Journals, researchers & institutions
Top journals
  • JAMA psychiatry1
  • Journal of clinical medicine1
Leading researchers
  • Bartoszek M1
  • Constantinescu O1
  • Croxford J1
  • Díaz-Álvarez A1
  • González-Rodríguez JL1
  • Hirsch S1
  • Kane S1
  • Kim E1
Leading institutions
free-text, unnormalised
  • Instituto de Investigación Biomédica de Salamanca de la FIESCYL (IBSAL-FIESCYL)1
  • John F. Kennedy Special Warfare Center and School1
  • Landstuhl Regional Medical Center1
  • Salamanca University1
  • Salamanca University Hospital1
  • Tripler Army Medical Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials